Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study.The Pharmacogenomics Journal
Date of this Version3-22-2016
Document TypeJournal Article
AbstractUp to 50% of multiple sclerosis (MS) patients do not respond to interferon-beta (IFN-β) treatment and determination of response requires lengthy clinical follow-up of up to 2 years. Response predictive genetic markers would significantly improve disease management. We aimed to identify IFN-β treatment response genetic marker(s) by performing a two-stage genome-wide association study (GWAS). The GWAS was carried out using data from 151 Australian MS patients from the ANZgene/WTCCC2 MS susceptibility GWAS (responder (R)=51, intermediate responders=24 and non-responders (NR)=76). Of the single-nucleotide polymorphisms (SNP) that were validated in an independent group of 479 IFN-β-treated MS patients from Australia, Spain and Italy (R=273 and NR=206), eight showed evidence of association with treatment response. Among the replicated associations, the strongest was observed for FHIT (Fragile Histidine Triad; combined P-value 6.74 × 10(-)(6)) and followed by variants in GAPVD1 (GTPase activating protein and VPS9 domains 1; combined P-value 5.83 × 10(-5)) and near ZNF697 (combined P-value 8.15 × 10(-5)).
Citation InformationS Mahurkar, M Moldovan, V Suppiah, M Sorosina, et al.. "Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study." The Pharmacogenomics Journal (2016) ISSN: 1473-1150
Available at: http://works.bepress.com/lotti_tajouri/40/